地舒单抗国内的价格

Is a RANK ligand (RANKL) inhibitor indicated for: the prevention of skeletal-related events in patients with bone metastases from solid tumors; Important limitations of use: denosumab is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.

So, what is the price of denosumab in China?

Domestic price of denosumab: China conditionally approved the listing of denosumab in May 2019. However, because it was conditionally approved and it was only on the market for five months, the domestic selling price of this drug cannot be collected.

The price of denosumab abroad: Desosumumab 120mg produced by the American company Amgen, the price is about 3000$. Due to the floating rate of viability, the price will be different. Please consult the medical companion for the specific price!

Denosumab is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B ligand (RANKL), inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density.

On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. For the first time, denosumab was approved in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA for marketing.

(denosumab) is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein necessary for osteoclasts to maintain their structure, function and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts.